Author/Authors :
Dhore، Rajendra نويسنده MBBS, M.D. (Medicine) Associate Professor, Department of Medicine. Dr. Panjabrao Deshmukh Medical College, Amravati Maharashtra , India , , Dhore، Akshay نويسنده M.D. (Medicine) P.G. Student Department of Medicine, Netaji Shubash Chandra Bosh ,Government Medical College, Jabalpur, Madhya. Pradesh , India , , Wasnik، Vinod نويسنده MBBS, M.D. (PSM) Associate Professor, Department of Community Medicine. Dr. Panjabrao Deshmukh .Medical College, Amravati Maharashtra ,India , , Jadhav، Nilesh نويسنده PG Student (MD Medicine) Department of Medicine. Dr. Panjabrao Deshmukh .Medical College, Amravati Maharashtra ,India ,
Abstract :
Six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (HbA1c), fasting blood sugar, postprandial blood sugar, and weight of 22 Indian obese patients with type 2 diabetes mellitus with no serious adverse events. Therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese type 2 diabetic patients
